rt-PA静脉溶栓治疗心源性及非心源性脑梗死的效果评价

Evaluation of the effect of rt-PA intravenous thrombolysis in the treatment of cardiogenic and non-cardiogenic cerebral infarction

目的:探讨重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓治疗心源性及非心源性脑梗死的效果。方法:选取2018年7月-2020年3月接受rt-PA静脉溶栓治疗的脑梗死患者112例,将其分为心源性脑梗死组和非心源性脑梗死组。比较两组患者不同时间改良Rankin量表(mRS)评分、美国国立卫生研究院卒中量表(NIHSS)评分及不良事件发生率。结果:两组患者mRS评分、NIHSS评分比较,差异无统计学意义(P>0.05);非心源性脑梗死组患者不良事件发生率低于心源性脑梗死组,差异有统计学意义(P<0.05)。结论:rt-PA静脉溶栓治疗心源性及非心源性脑梗死的效果均比较理想,但是心源性脑梗死患者不良事件较多,临床中应给予更多关注。

Objective:To evaluate the effect of rt-PA intravenous thrombolysis in the treatment of cardiogenic and non-cardiogenic cerebral infarction.Methods:From July 2018 to March 2020,112 cases of patients with cerebral infarction who received recombinant tissue plasminogen activator(rt-PA)intravenous thrombolysis were enrolled,they were divided into cardiogenic cerebral infarction group and non-cardiogenic cerebral infarction group.The mRS scale scores,NIHSS scale scores at different time periods and incidence of adverse events were compared between the two groups.Results:The scores of mRS and NIHSS were compared between the two groups,the differences were not statistically significant(P>0.05).The incidence of adverse events in non-cardiac cerebral infarction group was lower than that in cardiogenic cerebral infarction group,the difference was statistically significant(P<0.05).Conclusion:The rt-PA intravenous thrombolysis is effective in the treatment of cardiogenic and non-cardiogenic cerebral infarction,but there are many adverse events in patients with cardiogenic cerebral infarction,so more attention should be paid in clinic.